Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors.
Humans with Alzheimer's disease and mice genetically engineered to simulate it have abnormally low levels of an enzyme called EphB2 in memory centers of the brain. Improving EphB2 levels in such mice by gene therapy completely fixed their memory problems.
PerkinElmer, Inc. announced announced the release of its new cellular imaging software solution, the Columbus Scope platform, designed specifically for microscopy labs.
The Agilent Labware MiniHub from Agilent Automation Solutions is a rotating random-access device for presenting and storing SBS-format labware in laboratory automation systems.
Merrion Pharmaceuticals Plc announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds.
Provectus Pharmaceuticals, Inc. reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company’s Phase 2 trial of PV-10.
Trophos SA announced that recently presented data demonstrates that olesoxime, Trophos’ lead compound, is a promising candidate for neuroaxonal repair and remyelination in white matter diseases, notably multiple sclerosis.
Eli Lilly and Company and Acrux announced that the U.S. Food and Drug Administration has approved Axiron topical solution CIII for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly suspected of causing patients to commit suicide.
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow.
Contrary to widespread belief, patients with abnormal liver function who are given long-term statin treatment do not face an increased risk of liver disease. In fact, statins can improve liver function in patients with abnormal liver tests.
Acetylcholine is critical to the human nervous system, but it is also highly vulnerable. It can fall victim to inadvertent or deliberate poisoning by a class of compounds known as organophosphates—chemicals found both pesticides and weaponized nerve agents.